thalidomide has been researched along with Corneal Neovascularization in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Corneal Neovascularization: New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of thalidomide analogue CC-3052 on corneal neovascularization in the rabbit model." | 7.79 | The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits. ( Chung, SK; Lee, YK, 2013) |
| "Evaluate the effect of LASSBio-596, structurally designed as a new hybrid of thalidomide, on inflammatory corneal angiogenesis." | 7.78 | Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits. ( Amaral de Moraes, ME; Barreiro, EJ; Lima, LM; Odorico de Moraes, M; Ribeiro, JC; Ribeiro, MZ; Ricardo, NM; Vagnaldo Fechine, F, 2012) |
| "Thalidomide is an effective inhibitor of corneal angiogenesis and prolongs graft survival as measured by graft clarity in donor corneas in eyes with previous neovascularization secondary to alkali injury." | 7.71 | Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. ( Abbas, A; Feroze, AH; Hyman, GF; Khan, B, 2002) |
| "Thalidomide has a significant antiangiogenic effect against VEGF-induced neovasclar growth." | 5.30 | Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. ( Becker, MD; Joussen, AM; Kruse, FE; Rohrschneider, K; Völcker, HE, 1998) |
| "Thalidomide has inhibitory effects on angiogenesis in the corneal micropocket assay." | 5.30 | Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. ( Germann, T; Joussen, AM; Kirchhof, B, 1999) |
| "To evaluate the effect of thalidomide analogue CC-3052 on corneal neovascularization in the rabbit model." | 3.79 | The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits. ( Chung, SK; Lee, YK, 2013) |
| "Evaluate the effect of LASSBio-596, structurally designed as a new hybrid of thalidomide, on inflammatory corneal angiogenesis." | 3.78 | Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits. ( Amaral de Moraes, ME; Barreiro, EJ; Lima, LM; Odorico de Moraes, M; Ribeiro, JC; Ribeiro, MZ; Ricardo, NM; Vagnaldo Fechine, F, 2012) |
| "Thalidomide is an effective inhibitor of corneal angiogenesis and prolongs graft survival as measured by graft clarity in donor corneas in eyes with previous neovascularization secondary to alkali injury." | 3.71 | Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. ( Abbas, A; Feroze, AH; Hyman, GF; Khan, B, 2002) |
| ", 1991), we found that pentoxifylline and thalidomide potentiate each others antiangiogenic effect induced by human malignant melanoma cells in the cornea of Macaca arctoides monkeys." | 3.70 | Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration. ( Akhter, S; Ambrus, JL; Karakousis, CP; Kulaylat, M; Plavsic, L; Toumbis, CA, 2000) |
| "Thalidomide was first used during the 50's-60's, especially for morning sickness in pregnant women." | 2.42 | [Using thalidomide against pathological neovascularization]. ( Eisenkraft, A; Hourvitz, A; Luria, S; Robenshtok, E, 2003) |
| "Thalidomide has a significant antiangiogenic effect against VEGF-induced neovasclar growth." | 1.30 | Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. ( Becker, MD; Joussen, AM; Kruse, FE; Rohrschneider, K; Völcker, HE, 1998) |
| "Thalidomide has inhibitory effects on angiogenesis in the corneal micropocket assay." | 1.30 | Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. ( Germann, T; Joussen, AM; Kirchhof, B, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, B | 1 |
| Li, PK | 1 |
| Ma, JX | 1 |
| Chen, D | 1 |
| Lee, YK | 1 |
| Chung, SK | 1 |
| Ribeiro, JC | 1 |
| Vagnaldo Fechine, F | 1 |
| Ribeiro, MZ | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 1 |
| Ricardo, NM | 1 |
| Amaral de Moraes, ME | 1 |
| Odorico de Moraes, M | 1 |
| Abbas, A | 1 |
| Khan, B | 1 |
| Feroze, AH | 1 |
| Hyman, GF | 1 |
| Eisenkraft, A | 1 |
| Luria, S | 1 |
| Robenshtok, E | 1 |
| Hourvitz, A | 1 |
| Kenyon, BM | 1 |
| Browne, F | 1 |
| D'Amato, RJ | 1 |
| Kruse, FE | 1 |
| Joussen, AM | 2 |
| Rohrschneider, K | 1 |
| Becker, MD | 1 |
| Völcker, HE | 1 |
| Germann, T | 1 |
| Kirchhof, B | 1 |
| Ambrus, JL | 1 |
| Toumbis, CA | 1 |
| Karakousis, CP | 1 |
| Kulaylat, M | 1 |
| Akhter, S | 1 |
| Plavsic, L | 1 |
1 review available for thalidomide and Corneal Neovascularization
| Article | Year |
|---|---|
[Using thalidomide against pathological neovascularization].
Topics: Angiogenesis Inhibitors; Corneal Neovascularization; Humans; Neovascularization, Pathologic; Thalido | 2003 |
8 other studies available for thalidomide and Corneal Neovascularization
| Article | Year |
|---|---|
Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Cells, Cultured; Corneal Neovascularization; D | 2018 |
The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Biomarkers; Corneal Neovascularization; D | 2013 |
Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits.
Topics: Animals; Corneal Neovascularization; Dexamethasone; Disease Models, Animal; Glucocorticoids; Keratit | 2012 |
Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Burns, Chemical; Cornea; Corneal Injuries; Corneal Neovascularizat | 2002 |
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
Topics: Administration, Oral; Animals; Cornea; Corneal Neovascularization; Endothelial Growth Factors; Femal | 1997 |
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
Topics: Administration, Oral; Animals; Cornea; Corneal Neovascularization; Disease Models, Animal; Endotheli | 1998 |
Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Capillaries; Cornea; Corneal Neovascularizat | 1999 |
Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Cornea; Corneal Neovascularization; Drug Combinat | 2000 |